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Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-
CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are
available on real-world use.
Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital
admissions, work absenteeism, and quality of life (QOL).
Design: Prospective, observational, multicenter, cohort study.
Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII)
therapy starting in the Belgian RT-CGM reimbursement program.
Intervention: Initiation of RT-CGM reimbursement.
Main Outcome Measure: Hemoglobin A1c (HbA1c) evolution from baseline to 12 months.
Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimburse-
ment system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline
HbA1c was 7.7 6 0.9% (61 6 9.8 mmol/mol) and decreased to 7.4 6 0.8% (57 6 8.7 mmol/mol) at
12 months (P, 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed
stronger decrease in HbA1c at 4, 8, and 12 months compared with patients who started because of
hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized
for severe hypoglycemia or ketoacidosis in contrast to 4% (P, 0.0005) the following year,with decrease
in admission days from54 to 18per 100patient years (P, 0.0005). In the sameperiod,work absenteeism
decreased and QOL improved significantly, with strong decline in fear of hypoglycemia.
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Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers
improves HbA1c, fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for
acute diabetes complications decreased. (J Clin Endocrinol Metab 103: 1224–1232, 2018)
R eal-time continuous glucose monitoring (RT-CGM),as standalone device or in combination with an
external insulin pump [continuous subcutaneous insulin
infusion (CSII)], leads to improvements in HbA1c with
reduced risk of hypoglycemic events, as shown in ran-
domized controlled trials (RCTs) (1–3). New generations
of so-called sensor-augmented pump (SAP) systems are
able to reduce time spent in hypoglycemia by suspending
insulin infusion when glucose is (predicted to be) low
(4, 5).
Despite evidence from RCTs, reimbursement of RT-
CGM in most countries is lacking (6, 7). Up to now, few
real-world studies with RT-CGM have been conducted
(8, 9) even though many health care authorities are in-
terested in such analyses to decide on reimbursement and
to select the patient population who could benefit most
from such interventions (10).
Since September 2014, the Belgian health care au-
thority has authorized the reimbursement of RT-CGM
for patients with type 1 diabetes (T1D) using CSII and
treated in selected specialized diabetes centers. Selection
of patients was left to the discretion of the diabetes teams.
Reimbursement was granted for an initial period of
3 years as a pilot program, with selected centers being
legally obliged to prospectively analyze the impact of re-
imbursement on clinical outcome parameters, including
quality of life (QOL). This uncontrolled, observational
study fulfills this requirement and measured the effect of
RT-CGM reimbursement on hemoglobin A1c (HbA1c),
admissions for acute diabetes complications, QOL, and
hypoglycemia under real-world conditions.
Materials and Methods
Study design
In this multicenter prospective observational cohort study
[Reimbursement Study of Continuous Glucose Monitoring in
Belgium (RESCUE) trial], data from all patients who started in
the reimbursement program between September 2014 and
December 2016 were analyzed. Data were collected during
standardized clinical follow-up, as agreed by the centers offering
RT-CGM reimbursement.
Center and patient selection
The Belgian health care authority selected 17 specialized
diabetes centers based on sufficient experience with CSII, de-
fined as having at least 50 patients on CSII. In these centers,
reimbursement of RT-CGM could be offered to 25% of CSII
users. Selected centers were free to decide which patients with
T1D using CSII they would offer RT-CGM reimbursement.
Clinicians were free to decide, but minimum criteria for selec-
tionwere suggested in a nonrestrictive way by the Belgian health
care authority and included diagnosed with T1D .1 year ago,
using CSII therapy .6 months, difficult glycemic control (un-
defined), and motivated to use RT-CGM. Patients were ex-
pected to use RT-CGM.70% of the time and upload monthly
their RT-CGM data. Every patient who entered the re-
imbursement program was included, without exception, in the
RESCUE trial after informed consent. Collaborating centers
and number of patients contributed by each center can be found
in Supplemental Table 1.
Outcomes
Primary endpoint was evolution over time ofHbA1c between
baseline and 12 months after start of RT-CGM reimbursement.
Secondary endpoints were effect of RT-CGM on admissions for
acute diabetes complications (hypoglycemia and/or ketoaci-
dosis), work absenteeism, QOL, glucose variability (coefficient
of variation = standard deviation of the mean sensor glucose
values divided by the mean sensor glucose value, reported as a
percentage), percentage of time in hypoglycemia (,70 mg/dL;
,3.9 mmol/L), range (70 to 180 mg/dL; 3.9 to 10 mmol/L), and
hyperglycemia (.250 mg/dL; .13.9 mmol/L) (11). Other in-
vestigational outcomes were indications for RT-CGM use,
social and demographic characteristics of RT-CGM users, and
reasons for RT-CGM discontinuation.
Devices
A total of 337 (65%) patients used Medtronic MiniMed®
Paradigm insulin pumps (Medtronic, Northridge, CA), 117
(23%) patients usedRocheAccu-Chek® (Spirit or Aviva) Combo
insulin pumps (Roche Diabetes Care GmbH, Mannheim, Ger-
many), and 58 (11%) patients usedMedtronic MiniMed® 640G
insulin pump (Medtronic). Sensors used by patients were Med-
tronic MiniMed® Enlite® Sensor (Medtronic) (n = 382; 75%),
Dexcom G4® PLATINUM (Dexcom, Inc, San Diego, CA) (n =
121; 24%), and FreeStyle Navigator® II (Abbott Diabetes Care,
Alameda, CA) (n = 8; 2%).
Data collection
Prespecified clinical data were collected from a period of
12 months before until 14 months after start of the re-
imbursement program. Information about clinical parameters
was collected from clinical files at baseline, 4 months, and
12months after start of RT-CGM.HbA1c levels were averaged
for prespecified time points: prereimbursement/baseline
(pre = 212 months until 21 day), 4 months (62 months),
8 months (62months), and 12 months (62months) after start
of reimbursement.
Different questionnaires on patient-related outcomes were
presented to patients at baseline and after 12 months, and
scored manually. All questionnaires [SF-36 (12), Problem Areas
in Diabetes-short form (13–15), andHypoglycemia Fear Survey
(HFS)-Worry (16, 17)] were validated in both Belgian languages
(Dutch and French) and presented to patients in their mother
tongue (Supplemental Table 2).
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Patients were asked to keep standardized diaries. At baseline,
patients were asked to report on their diabetes management and
how many disease-related events they experienced in the year
prior to RT-CGM reimbursement. During the study, patients
were asked to report on their diabetes management and any
disease-related events monthly (Supplemental Table 3). Patient-
reported emergency room admissions and hospitalizations for
acute diabetes complications (hypoglycemia/ketoacidosis) were
validated using hospital records in the individual centers.
Self-monitoring of blood glucose (SMBG), CSII, and RT-CGM
datawere collected using diabetesmanagement software from the
differentmanufacturers (Medtronic: CareLink Pro; Roche: Accu-
Chek Smartpix and Accu-Chek 360°; and Dexcom: Dexcom
Studio). Data for the following time points were extracted and
averaged: data from up to 12 months prior to reimbursement
(only CSII and SMBG data = prereimbursement), from entry
in the reimbursement program (week 0 until week 2 for
RT-CGM data), 4 months (62 months) for RT-CGM data,
8 months (62 months) for RT-CGM data, and up to 12 months
(62 months) after start for RT-CGM data.
Indications for RT-CGM reimbursement
Indications for entering patients into the RT-CGM re-
imbursement systemwere collected using a drop-down selection
list to be filled out by the clinician who included the patient in
the reimbursement system (Supplemental Table 4). For the
analysis, indications were grouped into major headings, being
hypoglycemia (grouping patients having frequent serious hy-
poglycemic events, epilepsy with hypoglycemia, hypoglycemia
unawareness, very unstable blood glucose, and avoiding hy-
poglycemia for sport and/or professional reasons), insufficient
and variable glycemic control (poor glycemic control without
explanation and frequent ketoacidosis), pregnancy (being
pregnant or planning pregnancy), and other.
Ethics
The study protocol was approved by the coordinating in-
stitutional review board (Ethics Committee UZ Leuven) after
obtaining advice from the 16 local ethical committees. The study
was executed in line with the Good Clinical Practice guidelines
of the Declaration of Helsinki in its latest form.
Statistical analysis
With a linear mixed model, we evaluated HbA1c, percentage of
time in hypoglycemia, range, hyperglycemia, and glucose vari-
ability as a function of time, with a random effect of center to
handle the correlation between patients of the same center and an
unstructured covariance matrix for the four repeated measure-
ments within the same patient. For evolution ofHbA1c, values at 4,
8, and 12 months were compared with the average value
from212 months until21 day (pre = baseline). For the evolution
of percentage of time in hypoglycemia, range, hyperglycemia, and
glucose variability, values at 4, 8, and 12 months were compared
with the average value between start and 2 weeks. From the
multivariable normal distribution implied by the linear mixed
model, we derived the relation (r) between baseline HbA1c and
changes in HbA1c vs baseline. Taking regression to the mean into
account, the obtained correlation is not tested vs zero but vs the
correlation that is already expected purely based on regression to
the mean (18). By adding the main effect and the interaction with
time in the linear mixed model, we verified whether the following
variablesmoderated the changes inHbA1c: gender, age, bodymass
index, education level, duration of CSII therapy, previous RT-
CGM use, and indication for starting RT-CGM. Age, body mass
index, and duration of CSII therapy were entered as continuous
predictors. A multivariable model was obtained using a backward
selection approach based on the Akaike information criterion.
We evaluated whether the evolution of percentage of time in
hypoglycemia, target range, and hyperglycemia depended on
the indication to start RT-CGM, and on baseline HbA1c
(univariable analyses).
To evaluate the evolution of the proportion of patients who
reached target HbA1c (,7%; ,53 mmol/mol), we used a lo-
gistic regression model with generalized estimating equations.
Tukey corrections for multiple testing were applied for pairwise
comparisons between time points, in the linear mixed models as
well as in the logistic regression model.
Paired t tests were used to analyze changes in QOL between
baseline and 12 months on subjects with information at both time
points. Applying a Bonferroni correction, the a level was set at
0.005. To facilitate interpretation, Cohen d effect sizes are reported
(19). Differences in change of QOLmeasures were analyzed using
independent-samples t test or one-way analysis of variance.
With the McNemar test, proportions of patients with work
absenteeism andwith admissions due to hypoglycemia/ketoacidosis
were compared between 1 year prior to reimbursement and the
12-month follow-up period. Differences in admission days and
work absenteeism per 100 patient years were assessed with the
Wilcoxon signed-rank test. For these analyses, using Bonferroni
correction, the two-sided a-significance level was set at 0.006.
Patients who were incapable of working because of disability
were excluded in the latter analysis.
Statistical analyses were performed with SPSS software for
Windows (IBM SPSS Statistics version 23, Armonk, NY) or with
SAS software forWindows (version 9.4, SAS Institute, Cary, NC).
Results
Patient characteristics
Between September 2014 and December 2016, 515
patients with T1D on CSII benefited from the reim-
bursement of RT-CGM in 17 specialized diabetes centers
in Belgium. Over this period, 417 (81%) patients
had $12-month follow-up, 46 (9%) had ,12-month
follow-up, and 52 (10%) patients stopped using RT-
CGM. An overview of patients in the reimbursement
program can be found in Supplemental Fig. 1. Charac-
teristics of patients are shown in Table 1. Most patients
were female (n = 299, 59%), highly educated (n = 296,
64%), and Caucasian (n = 493, 97%), with a long history
of T1D, and 5.76 4.6 years of CSII use at baseline. Forty-
two percent of patients had limited experience with RT-
CGMbefore reimbursement (n = 215; median of 5months,
95% confidence interval 3 to 24). Thirty-five percent of
patients (n = 180) had one or more microvascular
complication, and 5% (n = 25) had macrovascular
complications. Impaired awareness of hypoglycemia
was common (n = 238, 47%). Mean baseline HbA1c
was 7.6 6 0.9% (60.0 6 9.8 mmol/mol).
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The main indication to start RT-CGM therapy was
hypoglycemia (n = 289, 56%), followed by insufficient
and variable glycemic control (n = 132, 26%) (Supple-
mental Table 4).
Patients used RT-CGM 87.5 6 8.2% of time over the
12-month period. Most frequent reasons for discontin-
uation were related to the system itself, such as alarm
fatigue (n = 18, 35%). Other reasons were ,70% usage
of RT-CGM (n = 17, 33%), local and/or technical
problems (n = 16, 31%), and no apparent benefit for
patient and/or physician (n = 12, 23%).
Evolution of HbA1c after introduction of
RT-CGM reimbursement
In terms of primary outcome, HbA1c was significantly
lower at 12 months [7.46 0.8% (57.06 8.7 mmol/mol)]
compared with baseline [7.7 6 0.9% (61.0 6 9.8 mmol/
mol), P , 0.0001] for the total population [Fig. 1(a)].
The proportion of patients who achieved HbA1c ,7%
(,53mmol/mol) increased from23%to33%at 12months
(P = 0.001). A stronger decrease in HbA1c was observed
in patients with higher baseline HbA1c, but only at
4 months this correlation exceeded the regression to the
mean effect (r = 20.49, P = 0.0002) [Fig. 1(b)]. At each
time point, the changes vs baseline differed significantly
between the groups defined by indication for entering the
RT-CGM program (P , 0.0001) [Fig. 1(c)]. In the
subgroup of patients who were using RT-CGM because
of insufficient and variable glycemic control, HbA1c
decreased from 8.2 6 0.9% (66.0 6 9.8 mmol/mol)
before reimbursement to 7.6 6 0.8% (60.0 6 8.7 mmol/
mol) after 12 months (P , 0.0001), whereas patients who
were using RT-CGM because of hypoglycemia had a slight
decrease inHbA1c from7.560.8% (58.068.7mmol/mol)
to 7.4 6 0.8% (57.0 6 8.7 mmol/mol) (P = 0.001). As
expected, women who used RT-CGM because of on-
going or planned pregnancy had the lowest baseline
HbA1c [7.2 6 0.7% (55.0 6 7.7 mmol/mol)], yet they
managed to decrease it even further to 6.6 6 0.7%
(49.0 6 7.7 mmol/mol) at 4 months (P , 0.0005), after
which it increased to 6.96 0.9% (52.06 9.8mmol/mol) at
12months (P=0.029 between 4 and 12months) [Fig. 1(c)].
In the multivariable analysis, only the indication for
entering the RT-CGM reimbursement system was an
independent predictor of changes in HbA1c at all follow-
up moments (P , 0.0001) (Supplemental Fig. 2).
Change of acute hospital admissions and work
absenteeism after introduction of
RT-CGM reimbursement
The number of patients who were admitted to emer-
gency room or hospital because of severe hypoglycemia
and/or ketoacidosis decreased from 16% the year prior to
Table 1. Baseline Characteristics of Adult Patients








Age (y) 42.2 (12.5)
BMI (kg/m2) 25.3 (3.8)
Education
Highera 296 (64%)
No higher 166 (36%)
Living alone 59 (12%)
Diabetes-related characteristics
Diabetes duration (y) 22.3 (11.6)
Age at diagnosis (y) 19.3 (11.4)
Insulin pump therapy 515 (100%)
Duration (y) 5.7 (4.6)




Macrovascular complications 25 (5%)
Acute myocardial infarction 11 (2%)
Peripheral arterial disease 7 (1%)
Cerebrovascular accident 5 (1%)
Heart failure 2 (0.4%)
Impaired awareness of hypoglycemiac 238 (47%)
Symptoms ,50 mg/dL (2.8 mmol/L) 172 (34%)
No symptoms ,50 mg/dL (2.8
mmol/L)
66 (13%)
HbA1c (%) 7.6 (0.9)
HbA1c (mmol/mol) 60 (9.8)
Average glycemia (mg/dL)d 163 (27)
Self-reported daily home glucose-meter
readings (number per day)c
5.2 (1.9)
Average percentage of blood glucose
readings per dayd
,50 mg/dL (2.8 mmol/L) (%) 2.6 (2.5)
,70 mg/dL (3.9 mmol/L) (%) 11.1 (5.7)
70–180 mg/dL (3.9–10 mmol/L) (%) 52.1 (12.5)
.180 mg/dL (10 mmol/L) (%) 36.1 (13.3)
.250 mg/dL (13.9 mmol/L) (%) 15.4 (9.7)
RT-CGM–related characteristics
Indication for RT-CGM therapy
Hypoglycemia 289 (56%)





RT-CGM use before reimbursement
No 300 (58%)
Yes 215 (42%)
Data are mean (standard deviation) or n (%).
Abbreviation: BMI, body mass index.
aDefined as graduated from university.
bPeripheral and/or autonomic neuropathy.
cBased on questionnaire filled out by patients or the clinical team.
dAverage value based on blood glucose readings in 12 months prior to
reimbursement.
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RT-CGM initiation to 4%during the year in the program
(P , 0.0005). The average number of days of diabetes-
related hospital admissions per 100 patient years over
12 months was significantly reduced compared with the
12-month period prior to reimbursement (54 at baseline
vs 18 days per 100 patient years, P , 0.0005), with
greatest benefit seen in hypoglycemia-related admissions.
The number of patients reporting diabetes-related work
absenteeism decreased (123 vs 36 patients, P , 0.001),
with less absenteeism days (from 495 to 234 days per 100
patient years after 12 months, P = 0.001) (Table 2).
Change in QOL after introduction of
RT-CGM reimbursement
Completion rate of questionnaires was 87% both at
baseline and after 12 months. Patients who filled out
QOL questionnaires at both time points did not differ
significantly in QOL at baseline from patients who filled
out the questionnaire only once. After 12 months of
reimbursement, a significant change in all but one general
measures of QOL was observed. Both diabetes-specific
measures (Problem Areas in Diabetes-short form and
HFS-II Worry) were significantly improved at 12 months
(Table 3). Based on effect sizes, improvement inQOLwas
largest in patients who had problems with hypoglycemia,
and weakest in patients with insufficient and variable
glycemic control (Table 3) as indication for implementing
RT-CGM, especially for general health, social func-
tioning, and HFS-II Worry.
Change of time in hypoglycemia, range, and
hyperglycemia after introduction of
RT-CGM reimbursement
In the total population, the percentage of measure-
ments ,70 mg/dL (3.9 mmol/L) based on SMBG data
was on average 11.1 6 5.7% 1 year before RT-CGM
reimbursement (Supplemental Fig. 3). Using RT-CGM
data, the percentage of measurements ,70 mg/dL
(3.9 mmol/L) was 5.6 6 3.8% in the first 2 weeks,
with a decline to 4.56 3.2% after 12 months (P = 0.002)
[Supplemental Fig. 3(a)]. This decline was seen in-
dependent of baseline HbA1c [Supplemental Fig. 3(b)] or
indication to start RT-CGM reimbursement [Supple-
mental Fig. 3(c)].
In contrast to time spent in hypoglycemia, time in
range (70 to 180 mg/dL; 3.9 to 10 mmol/L) or hyper-
glycemia (.250 mg/dL; .13.9 mmol/L) was greatest in
Figure 1. Evolution of HbA1c from before until 12 months after
start of the RT-CGM reimbursement program. Data points represent
mean (standard error) of HbA1c measurements per time point for (a)
the total population, (b) as a function of baseline HbA1c, and (c)
divided per indication to start RT-CGM therapy. Numbers under the
graphs represent number of patients who had data at the specific
time point. Note that in (c), the 14 subjects who entered the RT-
CGM program for other reasons are not included in the figure. In
(b), the model-based predictions (obtained from the multivariate
normal distribution) are averaged within the groups with baseline
values .8% (.64 mmol/mol), 7% to 8% (53 to 64 mmol/mol), and
,7% (,53 mmol/mol), respectively. ***P , 0.001; **P , 0.01;
and *P , 0.05 for the comparisons between HbA1c before
reimbursement and the time points after start (a, c). §§§P , 0.001;
§§P , 0.01; and §P , 0.05 for the relation between the variable
Figure 1. (Continued). and the change vs baseline [i.e., test if the
correlation between baseline HbA1c and the change in HbA1c
exceeds the regression to the mean effect in (b); test for the
interaction term in (c)].
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the first weeks after start of reimbursement, with a
worsening afterward (Fig. 2; Supplemental Fig. 3).
Glucose variability, as measured by mean coefficient of
variation (95%confidence interval) of RT-CGMreadings,
slightly decreased from 38.7% (38.0 to 39.4) in the first
2 weeks to 37.9% (37.2 to 38.6) at 12 months (P = 0.02).
Discussion
Results from our observational real-world cohort study
show that nationwide reimbursement of RT-CGM in
specialized diabetes centers for patients with T1D using
CSII resulted in lower HbA1c, less hospital admissions for
acute diabetes complications, and improvement in QOL.
Weobserved a clinically significant 0.3% (3.3mmol/mol)
reduction in HbA1c after 12 months for the total pop-
ulation. This demonstrates that a similar magnitude of
HbA1c reduction as reported in RCTs can be achieved in
real-world conditions. The SWITCH Study comparing
SAP to CSII showed a 0.5% (5.5 mmol/mol) decrease in
HbA1c after 6months in patients using RT-CGM.70%
of the time (20), and in the STAR 3 trial patients using
SAP had a 0.8% (8.7 mmol/mol) lower HbA1c at
12 months than those using multiple daily insulin in-
jections and SMBG (2). In line with the recent consensus
statement (11), our trial reports on time in hypoglyce-
mia, time in range, and glucose variability. A continued
decrease in time in hypoglycemia was observed after the
first weeks of RT-CGM use at the price of only a slight
decrease in time in range. This indicates that longer
use of RT-CGM helps in preventing hypoglycemic
events, which is important in a patient population
that was selected mainly on the basis of problematic
hypoglycemia.
Table 3. QOL Outcomes
































79.4 (21.1) 82.7 (21.2) ,0.0005 0.16 79.7 (21.1) 83.3 (20.7) ,0.0005 0.17 75.1 (23.1) 80.3 (22.3) 0.002 0.23 0.401
Role-physical 62.5 (27.1) 68.0 (26.8) ,0.0005 0.20 61.9 (27.0) 69.0 (27.1) ,0.0005 0.26 60.0 (27.5) 63.3 (26.6) 0.211 0.12 0.209
Bodily pain 71.8 (26.2) 74.4 (27.0) 0.033 0.10 71.1 (25.8) 74.7 (26.7) 0.020 0.14 67.7 (28.8) 69.2 (28.5) 0.569 0.05 0.484
General
health
49.5 (21.5) 54.1 (22.5) ,0.0005 0.21 49.4 (21.5) 56.3 (22.4) ,0.0005 0.32 47.6 (21.4) 48.6 (22.5) 0.644 0.05 0.016
Vitality 54.5 (19.3) 57.4 (19.5) 0.003 0.15 54.9 (19.3) 59.0 (19.1) 0.002 0.21 54.3 (19.6) 54.4 (20.1) 0.962 0.01 0.078
Social
functioning
70.0 (26.1) 76.3 (24.9) ,0.0005 0.24 69.1 (26.2) 77.7 (24.3) ,0.0005 0.33 69.9 (26.3) 72.0 (25.0) 0.407 0.08 0.038
Role-
emotional
70.8 (28.1) 76.4 (26.7) ,0.0005 0.20 69.9 (27.8) 76.7 (27.3) 0.001 0.24 69.2 (30.4) 74.0 (28.3) 0.170 0.16 0.623
Mental
health
65.2 (17.8) 68.8 (18.1) ,0.0005 0.20 64.3 (17.6) 68.8 (17.6) ,0.0005 0.26 67.7 (19.1) 68.4 (19.7) 0.747 0.04 0.110
PAID-SF 7.7 (4.9) 6.6 (4.7) ,0.0005 0.22 7.7 (4.8) 6.2 (4.5) ,0.0005 0.31 8.4 (5.3) 7.6 (5.0) 0.110 0.15 0.243
HFS Worry 18.6 (10.5) 15.1 (9.5) ,0.0005 0.33 19.4 (10.8) 15.4 (9.9) ,0.0005 0.47 15.4 (8.9) 14.4 (8.7) 0.381 0.11 0.018
Data are mean (standard deviation).
Abbreviations: PAID-SF, Problem Areas in Diabetes–Short Form; SF-36, Short Form 36.
aEffect size indicates a small effect (0.1–0.3), a medium effect (0.3–0.5), or a large effect (.0.5).
bP value for the difference between patients with indication for RT-CGM: hypoglycemia and insufficient and variable glycemic control.
Table 2. Evolution of Diabetes-Related Hospital Admissions and Work Absenteeism
Before Reimbursement
(n = 496)
12 Months of Reimbursement
(n = 379) P Value
Patients with
Hospitalizations due to hypoglycemia and/or
ketoacidosis
77 (16%) 14 (4%) ,0.0005
Hospitalizations due to hypoglycemia 59 (11%) 12 (3%) ,0.0005
Hospitalizations due to ketoacidosis 23 (5%) 4 (1%) 0.092
Work absenteeisma 123 (25%) 36 (9%) ,0.0005
Days (per 100 patient years) of
Hospitalizations due to hypoglycemia and/or
ketoacidosis
53.5 17.8 ,0.0005
Hospitalizations due to hypoglycemia 38.5 12.5 0.001
Hospitalizations due to ketoacidosis 14.9 5.3 0.220
Work absenteeism 494.5 233.8 0.001
Data are n (%).
aWork absenteeism of at least half a day. Patient-reported hospital admissions were validated by clinicians.
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Hospital admissions for acute diabetes complications
decreased significantly, in particular for severe hypo-
glycemia, to a similar extent as described with SAP with
low glucose-suspend function (21). Taking into account a
mean cost of V4,733 per hospitalization (source Uni-
versity Hospitals Leuven), it represents a nationwide cost
reduction of V345,509 during the RESCUE trial period.
Most RCTs do not assess the effect on such hospitali-
zations because usually patients with these events in their
recent history are excluded. In addition, few real-world
studies with RT-CGM have been conducted that in-
vestigated the effect on hospitalizations. In the IN-
TERPRET Study, a 12-month multinational real-world
study on SAP, incidence of hospital admissions due to
hypoglycemia even increased, possibly explained by low
sensor usage (;30%) (8). Of interest, we also observed a
decline in work absenteeism, which is a less visible (but
substantial) financial burden to society (22).
Patients in the RESCUE trial had a sensor usage of
87.5%, which is more than in many RCTs (1–3, 23, 24),
and in a study on real-world use based on the CareLink
database (25). We believe that an important motivator
for patients in our real-world setting to use the sen-
sor .70% of the time, as suggested by guidelines (26),
was that this was a prerequisite for prolongation of re-
imbursement clearly stipulated at start of the program to
each patient. We believe that this also contributed to the
very low discontinuation rate of RT-CGM use in our
study, which is lower than observed in the T1D Ex-
change Clinic Registry (27), in which 44% of patients
reported discontinuing RT-CGM use within 1 year.
Possible reasons for this differencemight be that patients
were aware that stopping RT-CGM would mean giving
up the possibility of RT-CGM reimbursement for at
least 3 years. Also, half of patients in our study had
impaired awareness of hypoglycemia and were de-
pendent on RT-CGM for managing their hypoglycemic
episodes.
In this study, QOL was prospectively evaluated in a
large real-world T1D population on RT-CGM and CSII
using validated questionnaires. Compared with a Euro-
pean study that evaluated QOL in adults with T1D on
CSII or multiple daily insulin injections, patients in the
RESCUE trial had a lower overall perceived health status
at baseline (28). Additionally, almost half of the patients
in the RESCUE trial reported problematic emotional
distress (15). QOL improved and fear for hypoglycemia
decreased in the total population, but most dramatically
in those who started RT-CGM because of hypoglycemia.
The RESCUE trial originated from a unique quality
control requirement imposed by the Belgian health care
authorities, linking reimbursement of RT-CGM to a
preplanned analysis of the results and their publication
in a peer-reviewed journal. Payers are often reluctant to
promote wider use of RT-CGM, due to its substantial
cost. Therefore, generally only a small proportion of
patients with T1D has access to reimbursement based on
Figure 2. Evolution of time in hypoglycemia, range, and
hyperglycemia before and until 12 months after start of the RT-CGM
reimbursement program. Symbols represent mean percentage of
SMBG measurements (a) ,70 mg/dL (3.9 mmol/L), (b) 70 to 180
mg/dL (3.9 to 10 mmol/L), and (c) .250 mg/dL (13.9 mmol/L) before
reimbursement and serve as a reference point. Connected data points
represent mean (standard error) percentage of RT-CGM measurements
(a) ,70 mg/dL (3.9 mmol/L), (b) 70 to 180 mg/dL (3.9 to 10 mmol/L),
and (c) .250 mg/dL (13.9 mmol/L) at the different time points after
start of reimbursement. Numbers under the graphs represent number
of patients who had data at the specific time point. ***P , 0.001;
**P , 0.01; and *P , 0.05 for the comparisons between RT-CGM
data point at 2 weeks and the later RT-CGM data points.
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criteria that vary per health insurance system (6, 7, 26, 29,
30). In the Belgian reimbursement system, diabetes teams
were free in choosing patients, but available funding was
limited to a fixed number of patients (;500 nationwide).
This unique situation forced the diabetes teams to choose
the patients whom they thought would benefit most from
RT-CGM. The teams, independently from each other or
from predefined criteria, mainly selected patients who
suffered from hypoglycemia, differing from another real-
world study in which glycemic instability and persistently
high HbA1c were the main indications to start SAP
therapy (8). We believe our data confirm the validity of
the Belgian strategy, as clinical teams eventually selected
highly motivated patients, who derived a high benefit
from the technology.
This study has limitations. First, because it is a non-
randomized observational trial, it is possible that factors
other than RT-CGM use (e.g., training, education, and
more intense contact with health care professionals when
starting RT-CGM therapy) contributed to the observed
benefits. Second, because of its observational nature, it
did not have a prospective control group. However, by
having patients as their own controls, the study was able
to show benefits linked to the introduction of RT-CGM.
A third weakness is the unavailability of blinded
RT-CGM measurements before start of reimbursement,
making it impossible to compare time spent in hypo-
glycemia, range, and hyperglycemia before and after
reimbursement. Finally, patients and diabetes teams were
free in choosing which combination of insulin pump and
sensor they would use. This resulted in a wide variety of
combinations across the program, making it impossible
to study the effectiveness of one RT-CGM device or to
compare different devices.
In conclusion, nationwide reimbursement of RT-
CGM for selected patients with T1D using CSII in spe-
cialized diabetes centers improved glycemic control and
lowered risk of acute diabetes-related hospitalizations.
Additionally, it decreased fear of hypoglycemia and led to
higher QOL. These results support the benefit of RT-
CGM use in a real-world setting.
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